Larger pipeline and increased support from regulatory authorities are setting up the orphan drug market for long-term success.
Melanie Senior
Advertisement
Melanie Senior, author, Evaluate’s Orphan Drug Report 2022
Articles by Melanie Senior
Advertisement
Latest Updated Articles
Orphan Drugs: From Niche to MainstreamPublished: June 15th 2022 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Bayer’s Lynkuet as First Dual Neurokinin Antagonist for Menopausal Hot Flashes
2
Direct-to-patient: pharma’s next power move
3
TrumpRx and the Dawn of Direct-to-Consumer Commercialization
4
AI Becomes Pharma’s New Operating System: Q&A with causaLens’ CEO and Co-Founder Darko Matovski
5
